Publication Name	World Journal of Gastrointestinal Surgery
Manuscript ID	64238
Country	China

Received	2021-02-14 12:29
Peer-Review Started	2021-02-14 12:34
To Make the First Decision
Return for Revision	2021-03-16 17:14
Revised	2021-03-25 02:10
Second Decision	2021-08-04 03:34
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-08-04 09:02
Articles in Press	2021-08-04 09:02
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-08-26 03:00
Typeset the Manuscript	2021-10-19 07:31
Publish the Manuscript Online	2021-10-26 08:04

ISSN	1948-9366 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Scientometrics
Article Title	Immunotherapy after liver transplantation: Where are we now?
Manuscript Source	Invited Manuscript
All Author List	Kin Pan Au and Kenneth Siu Ho Chok
ORCID	Author(s) ORCID Number Kin Pan Au http://orcid.org/0000-0002-7138-9805 Kenneth Siu Ho Chok http://orcid.org/0000-0001-7921-3807
Funding Agency and Grant Number
Corresponding Author	Kenneth Siu Ho Chok, FACS, FRCS (Ed), MBBS, MD, MS, Associate Professor, Department of Surgery and State Key Laboratory for Liver Research, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong NA, China. kennethchok@gmail.com
Key Words	Liver transplant; Hepatocellular carcinoma; Recurrence; Immunotherapy; Rejection; Survival
Core Tip	A literature review was performed to identify patients with prior liver transplantation and subsequent immunotherapy. Among the 28 included patients, the rejection rate was 32% (n = 9). Patients who developed acute rejection were given immunotherapy earlier after transplantation (median 2.9 years vs 5.3 years, P = 0.02) and their graft biopsies might be more frequently programmed death ligand-1 positive (100% vs 33%, P = 0.053). Among the 19 patients treated for hepatocellular carcinoma (HCC), the overall objective response rate was 11%. Rejection risk is the major obstacle to immunotherapy for post-liver transplant HCC recurrence.
Publish Date	2021-10-26 08:04
Citation	Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? World J Gastrointest Surg 2021; 13(10): 1267-1278
URL	https://www.wjgnet.com/1948-9366/full/v13/i10/1267.htm
DOI	https://dx.doi.org/10.4240/wjgs.v13.i10.1267

Full Article (PDF)	WJGS-13-1267.pdf
Full Article (Word)	WJGS-13-1267.docx
Manuscript File	64238-Review-FilipodiaCL.docx
Answering Reviewers	64238-Answering reviewers.pdf
Audio Core Tip	64238-Audio core tip.m4a
Biostatistics Review Certificate	64238-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	64238-Conflict-of-interest statement.pdf
Copyright License Agreement	64238-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64238-Language certificate.pdf
Peer-review Report	64238-Peer-review(s).pdf
Scientific Misconduct Check	64238-Scientific misconduct check.pdf
Scientific Editor Work List	64238-Scientific editor work list.pdf
CrossCheck Report	64238-CrossCheck report.pdf